Lilly Reports Strong Fourth-Quarter and Full-Year 2020 Financial Results

- Revenue in the fourth quarter of 2020 increased 22 percent, driven by volume growth of 24 percent. Excluding bamlanivimab revenue of $871 million, fourth-quarter 2020 revenue grew 7 percent. - Full-year 2020 revenue increased 10 percent, driven by volume growth of 15 percent.